CN Patent

CN118076340A — 眼用药物组合物及其用途

Assigned to Alcon Inc · Expires 2024-05-24 · 2y expired

What this patent protects

本文提供了包含(1R,2S,5R)‑2‑异丙基‑N‑(4‑甲氧基苯基)‑5‑甲基环己烷‑1‑甲酰胺(WS‑12)的眼用药物组合物，用于在有此需要的受试者中有效治疗干眼症，在有此需要的受试者中有效减轻干眼症，在有此需要的受试者中有效降低干眼症可能性，或用于在有此需要的受试者中治疗、预防或改善干眼症体征或症状。

USPTO Abstract

本文提供了包含(1R,2S,5R)‑2‑异丙基‑N‑(4‑甲氧基苯基)‑5‑甲基环己烷‑1‑甲酰胺(WS‑12)的眼用药物组合物，用于在有此需要的受试者中有效治疗干眼症，在有此需要的受试者中有效减轻干眼症，在有此需要的受试者中有效降低干眼症可能性，或用于在有此需要的受试者中治疗、预防或改善干眼症体征或症状。

Drugs covered by this patent

Patent Metadata

Patent number
CN118076340A
Jurisdiction
CN
Classification
—
Expires
2024-05-24
Drug substance claim
No
Drug product claim
No
Assignee
Alcon Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.